Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

MannKind cuts lengthy Afresa NDA

  • News

Executive Summary

MannKind had been pushing to submit an NDA for Afresa - the only inhaled insulin still in development - by the end of February. However, the Valencia, Calif. company announced Feb. 26 it is delaying the filing by approximately three weeks to reduce the size of the dossier by "several tens of thousands" of pages to make the document more reviewer-friendly; the "back-up" data will be available if requested by FDA. Announcing the specifics for the delay may not be the wisest decision. As Diabetic Investor's David Kliff notes Feb. 27, "This statement just might peak the agency's curiosity and create the impression that there might be something in those tens of thousands of pages that the company does not want the agency to see." MannKind has been retooling the positioning of Afresa as "ultra rapid-acting" insulin to separate it from Pfizer's failed Exubera (1"The Pink Sheet" DAILY, Feb. 18, 2009)

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Mismatch Between Growing Vaccine Pipeline and CDC’s ACIP Capacity

Keeping Track: Two Breakthrough Oncologics, Another Antibiotic Clear US FDA Along With Pfizer’s Hemophilia B Gene Therapy

Priority Review Vouchers: Tropical Disease Candidates Wait Years For FDA Action On Qualifying List

Pink Sheet Podcast: US FDA Biosimilar Strategy, Gene Therapy Accelerated Approvals, FDA v. Partisan Politics

See All
UsernamePublicRestriction

Register

PS050756

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By